Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An International Multicenter, Adaptive, Randomized Double-Blind, Placebo-Controlled Trial of the Safety, Tolerability and Efficacy of Anti-Coronavirus Hyperimmune Intravenous Immunoglobulin for the Treatment of Adult Hospitalized Patients at Onset of Clinical Progression of COVID-19

NCT04546581 is registered in ClinicalTrials.gov with University of Minnesota as lead sponsor.

NCT NCT04546581
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04546581 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An International Multicenter, Adaptive, Randomized Double-Blind, Placebo-Controlled Trial of the Safety, Tolerability and Efficacy of Anti-Coronavirus Hyperimmune Intravenous Immunoglobulin for the Treatment of Adult Hospitalized Patients at Onset of Clinical Progression of COVID-19
Lead sponsor
University of Minnesota
Phase
Phase 3
Overall status
Completed
Start date
October 8, 2020
Completion date
May 21, 2021
Enrollment
593 (actual)
Sites
39

Conditions

As the registry lists them; a condition with its own page is linked.

covid, covid-19, sars (severe acute respiratory syndrome), sars-cov-2